Clinical trials: Type 2 Diabetes (T2D)
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effective as Insulin Glargine as…
- Trial name
- NCT00283751
- Testing
- insulin detemir, insulin glargine
- Where
- 96 sites in United States, Austria and 5 more
- Volunteers
- 583 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.
This is an escalating dose study in subjects with T2DM, which will consist of four overlapping cohorts receiving 6 days of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics.
- Trial name
- NCT00733577
- Testing
- SB756050
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Type 1 or Type 2 Diabetes
Bigfoot Unity Real World Study
This study is observational, designed to collect real world use and safety data for those using the Bigfoot Unity Diabetes Management System for 12 months.
- Trial name
- BURST (NCT05088265)
- Testing
- Bigfoot Unity Diabetes Management System
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Bigfoot Biomedical Inc.
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects with Type 2 Diabetes Mellitus
- Trial name
- NCT02933853
- Testing
- Faster-acting insulin aspart, Insulin Aspart
- Where
- Austria
- Volunteers
- 61 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus (T2DM)
Clinical Study to Evaluate the Food Effect of CKD-383 0.5/10/1000mg in Healthy Volunteers
This study is a randomized, open-label, single dose, crossover study to evaluate the food effect of CKD-383 in healthy volunteers
- Trial name
- CKD-383 FDI P1 (NCT06695572)
- Testing
- CKD-383
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2
A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers
Insulin icodec is a new medicine which is under development for use in humans and is not yet available at the pharmacy. It is being developed for the treatment of diabetes, a condition that causes high blood sugar levels.
- Trial name
- NCT05790681
- Testing
- Insulin icodec
- Where
- 21 sites in United States
- Volunteers
- 18 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the effect of aleglitazar on renal function, the renin-angiotensin system and the pharmacokinetics of lisinopril in patients with type 2…
- Trial name
- NCT01398267
- Testing
- aleglitazar, lisinopril
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Glycemic Control
Glycemic Response in Adults With Type 2 Diabetes
This is a randomized, controlled, crossover study to compare the effects of two treatments on postprandial glucose in adults with type 2 diabetes.
- Trial name
- NCT05166200
- Testing
- Experimental Formula, Test Meal
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Abbott Nutrition
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes
This study is conducted in Africa, Asia and Europe. The aim of this study is to investigate biphasic insulin aspart 30 (NovoMix® 30) alone or in combination with oral hypoglycaemic agent (OHA) for type 2 diabetes management in…
- Trial name
- PRESENT (NCT01536600)
- Testing
- biphasic insulin aspart 30
- Where
- South Korea
- Volunteers
- 33,010 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone.
The purpose of this study is to asses changes in glycosylated hemoglobin, fasting blood lipids and genetic polymorphism's in peroxisomal proliferator activated receptors--gamma receptor after 6 months of pioglitazone, once daily…
- Trial name
- NCT00449553
- Testing
- Pioglitazone and sulphonylurea, Pioglitazone and metformin
- Where
- 4 sites in Denmark, Iceland and 2 more
- Volunteers
- 326 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3532226 in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT05407961
- Testing
- LY3532226, Dulaglutide
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes
B2611003 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 6 treatments for 3 months.
- Trial name
- NCT01338870
- Testing
- 25 mg PF-04991532, 75 mg PF-04991532, 150 mg PF-04991532
- Where
- 42 sites in United States, Canada and 4 more
- Volunteers
- 301 people
- Sponsor
- Pfizer
Type2 Diabetes
Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults With Type 2 Diabetes Mellitus
Evaluation of Efficacy and Safety of Curalin As Add-On Therapy in Adults with Type 2 Diabetes Mellitus
- Trial name
- NCT05631431
- Testing
- Curalin
- Where
- 4 sites in Israel
- Volunteers
- 135 people
- Sponsor
- CuraLife
Type 2 Diabetes Mellitus
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
Primary Objective: To test the hypothesis that basal insulin based treatment (G+) is noninferior to twice-daily premixed insulin (PM-2) in term of hemoglobin A1c (glycosylated hemoglobin, HbA1c) reduction from baseline to end of…
- Trial name
- SWITCH (NCT03359837)
- Testing
- INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Sanofi
Type 2 Diabetes
Safety and Efficacy Study of Subjects That Are Taking Saxagliptin Added Onto Metformin XR Compared to Subjects Taking Metformin XR Alone
This protocol will compare 24 hour glucose control for subject taking saxagliptin and metformin extended release (XR) versus metformin XR alone
- Trial name
- NCT00683657
- Testing
- Saxagliptin
- Where
- 27 sites in United States, Argentina and 6 more
- Volunteers
- 93 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications
Dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagonlike peptide-1 (GLP-1) mimetics or analogs, which rely on the gastrointestinal hormones that are part of the incretin system for the treatment of T2DM, provide a therapeutic…
- Trial name
- PREFER (NCT01518101)
- Testing
- Vildagliptin/ Metformin, Liraglutide, Metformin
- Where
- 8 sites in Germany
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus
Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs
Primary Objective: To compare LixiLan to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to week 26 in patients with type 2 diabetes mellitus.
- Trial name
- LIXILAN JP-L (NCT02752412)
- Testing
- Insulin glargine/Lixisenatide (HOE901/AVE0010), Insulin glargine U100 (HOE901), Metformin
- Where
- 122 sites in Japan
- Volunteers
- 513 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes
HbA1c is widely used as the gold standard for evaluating glycemic control. However, in patients who need adjusting hypoglycemic regimen, A1c was not a sensitive marker.
- Trial name
- NCT05227677
- Testing
- GA guided anti-diabetic therapy adjustment, current guidelines to adjust treatment
- Where
- 7 sites in China
- Volunteers
- 200 people
- Sponsor
- Asahi Kasei Therapeutics Corporation
Type 2 Diabetes Mellitus
Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes
A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal/bolus insulin therapy or basal-only insulin…
- Trial name
- EVOLVE (NCT07521475)
- Testing
- Device: Omnipod M System with study CGM, Standard Therapy plus study CGM
- Where
- 27 sites in United States
- Volunteers
- 350 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects
The purpose of this 32 week study is to demonstrate that fixed-dose combination treatment with rosiglitazone/metformin will safely and effectively control glycemia as first line oral therapy in subjects type 2 diabetes.
- Trial name
- NCT00499707
- Testing
- rosiglitazone maleate/metformin hydrochloride
- Where
- 102 sites in United States, Australia and 5 more
- Volunteers
- 453 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.